Power Law company profile

Hybio Pharmaceutical

Biotech & Life Sciences · Shenzhen, China · Founded 1998 · IPO 2011 Thoroughbred

Shenzhen Hybio Pharmaceutical is a high-tech enterprise which engaged in research, development, production, and sales of polypeptide drugs

Valuation

$2.77B

Market cap · May/2026

Revenue

$133M

Latest reported FY

EBITDA

$46M

Latest reported FY

Featured in $10B+ revenueThoroughbred · Power Law outcome

Investors

2 investors on Hybio Pharmaceutical's cap table

Sourced from Dealroom's funding history. Tap any card for that investor's profile.

Series A 2 investors entered at this stage

SAIF Partners

Shenzhen Capital Group

Global footprint

Where Hybio Pharmaceutical has talent and traffic

Workforce by country

2 countries with
team presence

🇨🇳 China98.5%

🇸🇪 Sweden5.9%

2 countries shown

Web traffic by country

630 monthly visits
across markets

🇺🇸 United States95.2%

Top 1 markets shown

Market sentiment

What the market is saying about Hybio Pharmaceutical

An AI-synthesized read of the highest-engagement posts about Hybio Pharmaceutical on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Hybio Pharmaceutical on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles